#high risk high return

LGVN, the biotech stock that jumped 70% today — real opportunity or a one-shot trap?

Today’s LGVN move was not about earnings but about a capital raise of up to $30 million lining up with its clinical timeline, so the right lens is this: the company now has more breathing room financially, but dilution risk and volatility came with it.